Insider Transactions in Q1 2022 at Kiniksa Pharmaceuticals, Ltd. (KNSA)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 21
2022
|
Eben Tessari CHIEF OPERATING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,461
-1.29%
|
$14,610
$10.98 P/Share
|
|
Mar 21
2022
|
Eben Tessari CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,611
+3.9%
|
-
|
|
Mar 21
2022
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,120
-15.64%
|
$11,200
$10.98 P/Share
|
|
Mar 21
2022
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,231
+31.09%
|
-
|
|
Mar 21
2022
|
John F. Paolini CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,686
-4.58%
|
$16,860
$10.98 P/Share
|
|
Mar 21
2022
|
John F. Paolini CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,676
+13.36%
|
-
|
|
Mar 21
2022
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,047
-15.64%
|
$10,470
$10.98 P/Share
|
|
Mar 21
2022
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,019
+31.08%
|
-
|
|
Mar 21
2022
|
Ross Moat CHIEF COMMERCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,240
-14.4%
|
$12,400
$10.98 P/Share
|
|
Mar 21
2022
|
Ross Moat CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,270
+20.86%
|
-
|
|
Mar 21
2022
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,446
-23.47%
|
$54,460
$10.98 P/Share
|
|
Mar 21
2022
|
Sanj K Patel CHAIRMAN & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
18,555
+44.44%
|
-
|
|
Mar 16
2022
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
303
-7.62%
|
$3,030
$10.13 P/Share
|
|
Mar 16
2022
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
872
+17.98%
|
-
|
|
Mar 16
2022
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,922
-29.26%
|
$19,220
$10.13 P/Share
|
|
Mar 16
2022
|
Sanj K Patel CHAIRMAN & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,569
+50.0%
|
-
|
|
Mar 16
2022
|
John F. Paolini CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
598
-1.88%
|
$5,980
$10.13 P/Share
|
|
Mar 16
2022
|
John F. Paolini CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,725
+5.16%
|
-
|
|
Mar 16
2022
|
Eben Tessari CHIEF OPERATING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
681
-0.62%
|
$6,810
$10.13 P/Share
|
|
Mar 16
2022
|
Eben Tessari CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,964
+1.76%
|
-
|
|
Mar 16
2022
|
Ross Moat CHIEF COMMERCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
544
-7.9%
|
$5,440
$10.13 P/Share
|
|
Mar 16
2022
|
Ross Moat CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
995
+12.63%
|
-
|
|
Mar 16
2022
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
269
-6.41%
|
$2,690
$10.13 P/Share
|
|
Mar 16
2022
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
775
+15.58%
|
-
|
|
Jan 15
2022
|
Eben Tessari CHIEF OPERATING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
970
+0.89%
|
$8,730
$9.63 P/Share
|
|
Jan 15
2022
|
Ross Moat CHIEF COMMERCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
1,546
+20.79%
|
$13,914
$9.63 P/Share
|
|
Jan 15
2022
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
653
+16.02%
|
$5,877
$9.63 P/Share
|